Artificial intelligence (AI) is mainly for the design a new drugs, finding new drug combinations and as well as deliver the clinical trials within minutes based on it. AI plays an important role in the disease identification, clinical trials research and drug discovery. Pharmaceutical industry can accelerate innovation by using technologies advancements. Generally, AI majorly stores a large amount of information and process it at a very high speed. A computer program with AI can answer the generic question it is meant to solve. Many big pharmaceutical companies investing in AI in order to develop better diagnosis or biomarker, to identify drug targets and to design new drugs and products. In March 2012, Merk partnership with numerate, focusing on developing novel small molecule drug which leas for CVS disease target. Robotics plays an active role in developing medical device. The production is highly regulated and developed by food and drug administration. Manufactures use robotics to minimize the cost. In December, 2016 Pfizer and IBM announced partnership to accelerate drug discovery in immuno-oncology. Mitsui and NVIDIA announce Japan's First Generative AI supercomputers for Pharmaceutical Industry. A recent paper in Nature reported that the integration of AI into the drug discovery and development increased by almost 40% in 2022. According to Global Genes, nearly 95% of rare disease don’t have FDA approved treatment or cures. Thanks to AI innovative abilities, the scenario is rapidly changing for the better. Artificial Intelligence (AI), in Drug Discovery Global Market, The market is expected to recover after the COVID-19 crisis at a great rate of about 43% and reach $1.1 billion through 2023.